skip to Main Content
 

Cutting Through the Noise: Market Evolution and Pathways to Access for COVID-19 Vaccines and Therapeutics 

  • This page as PDF

Summary

Avalere experts discussed the marketplace for COVID-19 vaccines and therapeutics, including key decision points for regulatory pathways, pricing, and distribution scenarios for optimal US and EX-US market access. 
Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.

With hundreds of vaccine and therapeutic candidates in the pipeline, planning ahead for patient access is vital. This uncharted territory provokes important questions about regulatory pathways, pricing, government procurement, coverage, access, distribution, and more.  Avalere experts explored these questions and tipping pointsas well as the necessary market access strategies. 

Key Topics

  • FDA regulatory considerations and downstream implications 
  • Coverage and access challenges 
  • Pricing, procurement, and distributionscenarios 
  • Potential 2020 election impacts on the COVID-19 response

Panelists

Moderator
Elizabeth Carpenter , President

As president of Avalere Health, Elizabeth Carpenter is responsible for the firm’s consulting, sales, and operational functions.

Speaker
Kelly L. George , Principal, Market Access & Reimbursement

Kelly L. George, PhD, RAC, supports clients in navigating the FDA policy environment for the development and lifecycle of drugs and biologics.

Speaker
Richard Hughes IV , Managing Director

Richard Hughes IV leads Avalere’s vaccines team, which supports clients with vaccine policy, market access and evidence strategies.

Speaker
John C. Neal , Managing Director, Commercialization & Regulatory Strategy

John Neal partners with pharmaceutical and biotechnology clients to develop market access assessments and launch strategies to ensure successful asset commercialization.

Webinar: Decoding the CY 2025 Advance Notice Join Avalere’s healthcare policy experts as they dissect the CY 2025 Medicare Advantage Advance Notice and discuss the future trajectory of MA in Part D and potential outcomes, headwinds, and tailwinds for health plans. Learn More
Watch the Recording
From beginning to end, our team synergy
produces measurable results. Let's work together.

Sign up to receive more insights about Vaccines and Public Health
Please enter your email address to be notified when new Vaccines and Public Health insights are published.

Back To Top